Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Broad variability in phar… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Broad variability in pharmacokinetics of GH following rhGH injections in children

Artikel i vetenskaplig tidskrift
Författare E. Lundberg
B. Andersson
B. Kristrom
Sten Rosberg
Kerstin Albertsson-Wikland
Publicerad i Growth Hormone & Igf Research
Volym 40
Sidor 61-68
ISSN 1096-6374
Publiceringsår 2018
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 61-68
Språk en
Länkar dx.doi.org/10.1016/j.ghir.2018.01.0...
Ämnesord Intra-individual variation, Inter-individual variation, GH-deficiency, Non-GH-deficiency, GH-treatment, Cmax, AUC, GH-peak, GH-trough, growth-hormone gh, deficient children, binding-protein, prepubertal, children, pharmacological aspects, hypophysectomized rats, lymphatic, transport, short stature, factor-i, igf-i, Cell Biology, Endocrinology & Metabolism,
Ämneskategorier Klinisk medicin

Sammanfattning

Objective: Daily subcutaneous self-injection of GH is used worldwide to treat short stature in childhood; longitudinal data on the impact of this regimen on GH-uptake are lacking. Design: Children with/without GH-deficiency participating in clinical trials were followed prospectively ( s 8 times). Blood was sampled pre-GH-injection (dose GH(33)/GH(67) mu g/kg) and either every 30 min thereafter for 24 h (Experimental-setting; 59 GH-curves/15 children); or every 2 h thereafter for 16 h (Clinical-setting; 429 GHcurves/117 children). Pharmacokinetics were estimated by time T-max (h) of maximal GH-concentration (C-max , mU/L) and area under the curve for 16 h (AUC, mU/L * h). Results: In the Clinical-setting, median C-max was 71 mU/L and AUC was 534 mU/L * h, with coefficients of variation for intra-individual variation of 39% and 36%, respectively, and inter-individual variation of 44% and 42%, respectively. 43% of C-max and AUC variability was explained by GH-dose and proxies for injection depth (baseline GH-level, GH(peak) width, BMISDS). In the Experimental- versus Clinical-setting, 85% and 40% of GH-curves, respectively, reached zero-levels within 24 h. A longer duration was found following a more superficial GH-injection. Spontaneous GH-peaks were identified already 6 h after the GH-injection in about half of the curves of both GHD and non-GHD patients. Conclusion: Very broad intra-individual and inter-individual variability was found. A high GH-peak will optimize growth effects; the highest C-max was found after a deep injection of GH at the higher dose and concentration. In as many as 60% of the children, GH remained detectable in serum after 24 h; a constant GH-level will promote IGF-I and metabolic effects.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?